Position Summary  MBX Biosciences is seeking an experienced and dynamic Senior Director of Medical Writing to establish and lead our Medical Writing department. This full-time leadership role will be instrumental in building a high-performing team and developing robust processes to support clinical and regulatory documentation across the organization. The successful candidate will be responsible for overseeing the creation of high-quality clinical and regulatory documents, ensuring alignment with industry standards and global regulatory requirements. This role requires exceptional leadership, deep expertise in medical writing, and a collaborative mindset to work effectively across cross-functional teams, including Clinical Development, Regulatory Affairs, Quality, and Program Management. This individual will report directly to the Senior Vice President of Regulatory &amp; Quality and will play a key role in shaping the strategic direction of medical writing within the company.    Key Responsibilities   <ul> <li>Lead and manage the Medical Writing team (including internal and external writers), providing guidance, mentorship, and professional development opportunities. </li> <li>Oversee the preparation, review, and submission of clinical and regulatory documents, including clinical study reports, protocols, investigator brochures, and regulatory submissions. </li> <li>Ensure all documents are accurate, scientifically sound, and compliant with regulatory guidelines and company standards. </li> <li>Collaborate with clinical, regulatory, and scientific teams to gather and interpret data, ensuring clear and effective communication of complex scientific information. </li> <li>Develop and implement medical writing processes, templates, and best practices to enhance efficiency and quality. </li> <li>Stay current with industry trends, regulatory requirements, and best practices in medical writing. </li> <li>Represent the Medical Writing function in cross-functional meetings and contribute to strategic planning and decision-making. </li> <li>Manage timelines and resources to ensure timely completion of projects. </li> <li>Other responsibilities as assigned.  </li> </ul> Education &amp; Qualifications   <ul> <li>Advanced degree in life sciences, medical writing, or a related field (PhD, MD, or equivalent preferred). </li> <li>15+ years of medical writing experience in the biotechnology or pharmaceutical industry. </li> <li>Proven track record of leading and managing a team of medical writers. </li> <li>Extensive knowledge of regulatory requirements and guidelines (e.g., ICH, FDA, EMA). </li> <li>Excellent written and verbal communication skills, with the ability to convey complex scientific information clearly and concisely. </li> <li>Excellent problem-solving skills, strategic thinking, and ability to work in a fast-paced, collaborative environment. </li> <li>Outstanding scientific leadership and collaboration skills.  </li> <li>Outstanding interpersonal skills, self-awareness, and ability to manage team dynamics. </li> </ul> Company Overview: MBX Biosciences, Inc. (NASDAQ: MBX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at <a href="http://www.mbxbio.com">www.mbxbio.com </a>and follow us on LinkedIn.  EEO Statement:  MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.